Eva Visser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eva Visser has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Christianne Johanna Buskens
Department of Surgery, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands
5 shared publications Laurents P S Stassen
Department of Surgery, Nutrim Institute for Nutrition and Translational Research in Metabolism, Maastricht University , Maastricht
4 shared publicationsLianne Heuthorst
Department of Surgery Amsterdam University Medical Centres University of Amsterdam Amsterdam The Netherlands
4 shared publicationsAndré D’hOore
Department of Abdominal Surgery, UZ Leuven , Leuven
3 shared publications- Gabriele Bislenghi
Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium
3 shared publications Willem A Bemelman
Department of Surgery, Amsterdam University Medical Centre , Amsterdam
3 shared publications
Latest Publications
- Open Access
Efficacy of Advanced Medical Therapies in Patients With Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta‐Analysis
Background: To evaluate the absolute efficacy of approved advanced medical therapies (biologicals or small molecules) in adults with moderately to severely active ulcerative colitis (UC), compared with placebo or active comparators. Methods: We included Phase 3 and 4 randomised controlled trials (RCTs) evaluating FDA‐ or EMA‐approved advanced therapies in adults with moderately to severely active UC. PubMed, EMBASE, Cochrane, and major congress abstracts were searched through October 2024. Eligible RCTs compared these therapies to placebo or an active comparator and reported clinical remission, clinical response, endoscopic remission, and/or histological remission. Our primary outcome was clinical remission after induction (defined as a Mayo score ≤ 2 with no individual subscore > 1, including the endoscopic subscore). Random‐effects models estimated pooled absolute differences in outcome rates (risk differences; RDs) for induction and maintenance. Certainty of evidence was assessed using GRADE. Results: The search yielded 7712 records, of which 25 RCTs (38 cohorts; 15,460 patients) met inclusion criteria. Of these, 20 RCTs (25 cohorts; 11,476 patients) reported induction outcomes, and 18 RCTs (19 cohorts; 6692 patients) reported maintenance outcomes. The pooled absolute difference (RD) for clinical remission after induction was +13.1% (95% CI: 10.3–16.0), increasing to +21.1% (95% CI: 16.4–25.7) for maintenance. Clinical response also favoured intervention, with RDs of +24.2% (95% CI: 19.7–28.6) for induction and +26.6% (95% CI: 20.3–33.0) for maintenance. Endoscopic remission was less frequently reported, and showed smaller but significant effects (induction RD +8.2%, 95% CI: 4.7–11.8; maintenance +13.6%, 95% CI: 8.5–18.7). Histological remission RDs were +12.5% (95% CI: 6.6–18.4) and +15.5% (95% CI: 9.0–22.0), respectively. Certainty of evidence was high for clinical remission and moderate‐to‐low for other outcomes due to limited reporting and heterogeneity. Conclusions: Advanced therapies favoured significant absolute benefits in inducing and maintaining remission in moderate‐to‐severe UC. These results provide a benchmark for future trials and non‐pharmacological interventions. Trail Registration: This study was registered in PROSPERO (CRD42024599272)
Open AccessEfficacy of Advanced Medical Therapies in Patients With Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta‐Analysis
Background: To evaluate the absolute efficacy of approved advanced medical therapies (biologicals or small molecules) in adults with moderately to severely active ulcerative colitis (UC), compared with placebo or active comparators. Methods: We included Phase 3 and 4 randomised controlled trials (RCTs) evaluating FDA‐ or EMA‐approved advanced therapies in adults with moderately to severely active UC. PubMed, EMBASE, Cochrane, and major congress abstracts were searched through October 2024. Eligible RCTs compared these therapies to placebo or an active comparator and reported clinical remission, clinical response, endoscopic remission, and/or histological remission. Our primary outcome was clinical remission after induction (defined as a Mayo score ≤ 2 with no individual subscore > 1, including the endoscopic subscore). Random‐effects models estimated pooled absolute differences in outcome rates (risk differences; RDs) for induction and maintenance. Certainty of evidence was assessed using GRADE. Results: The search yielded 7712 records, of which 25 RCTs (38 cohorts; 15,460 patients) met inclusion criteria. Of these, 20 RCTs (25 cohorts; 11,476 patients) reported induction outcomes, and 18 RCTs (19 cohorts; 6692 patients) reported maintenance outcomes. The pooled absolute difference (RD) for clinical remission after induction was +13.1% (95% CI: 10.3–16.0), increasing to +21.1% (95% CI: 16.4–25.7) for maintenance. Clinical response also favoured intervention, with RDs of +24.2% (95% CI: 19.7–28.6) for induction and +26.6% (95% CI: 20.3–33.0) for maintenance. Endoscopic remission was less frequently reported, and showed smaller but significant effects (induction RD +8.2%, 95% CI: 4.7–11.8; maintenance +13.6%, 95% CI: 8.5–18.7). Histological remission RDs were +12.5% (95% CI: 6.6–18.4) and +15.5% (95% CI: 9.0–22.0), respectively. Certainty of evidence was high for clinical remission and moderate‐to‐low for other outcomes due to limited reporting and heterogeneity. Conclusions: Advanced therapies favoured significant absolute benefits in inducing and maintaining remission in moderate‐to‐severe UC. These results provide a benchmark for future trials and non‐pharmacological interventions. Trail Registration: This study was registered in PROSPERO (CRD42024599272)
- Top Cited Papers
- 7 July 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (7)
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
- 7 July 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (7)
Top Cited PapersECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
- 7 June 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (6)
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment
This is the second of two articles presenting the European Crohn’s and Colitis Organisation [ECCO] evidence‑based consensus guidelines on the management of adult patients with ulcerative colitis [UC]. The first article covers the medical management of UC, including acute severe colitis. The present article addresses the surgical management of medically refractory UC, including the general surgical approach and perioperative optimisation, surgical strategies and techniques, and recommended levels of centre expertise and surgical specialisation. Together, these two articles aim to inform shared decision‑making and to guide clinicians and healthcare professionals involved in the care of patients with UC, drawing on the best available evidence.
- 7 June 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (6)
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment
This is the second of two articles presenting the European Crohn’s and Colitis Organisation [ECCO] evidence‑based consensus guidelines on the management of adult patients with ulcerative colitis [UC]. The first article covers the medical management of UC, including acute severe colitis. The present article addresses the surgical management of medically refractory UC, including the general surgical approach and perioperative optimisation, surgical strategies and techniques, and recommended levels of centre expertise and surgical specialisation. Together, these two articles aim to inform shared decision‑making and to guide clinicians and healthcare professionals involved in the care of patients with UC, drawing on the best available evidence.
- Open Access
Response to Appendectomy in Active Ulcerative Colitis Depends on Appendiceal Phenotypic Subtype Combined With Distinct Immunological Activity
Background: Recent clinical trials have shown a promising role for appendectomy in the treatment of ulcerative colitis (UC). However, as with medical treatment, only a subset of patients responds to the intervention. A lack of predictive markers and knowledge on the mechanism of action of appendectomy in UC currently precludes affective patient selection. Methods: We performed transcriptional profiling and cellular deconvolution on the appendices obtained in the course of the recent clinical studies. Data were verified by immunohistochemistry. Results: When comparing responders to nonresponders, initially very few differentially expressed genes were observed (7 up and 6 down). However, unsupervised clustering revealed a dichotomy in the samples which was the results of underlying phenotypic differences. One group mainly displayed stromal characteristic, whereas the other expressed intestinal epithelial genes. These data were verified by deconvolution and immunohistochemistry. Importantly, within each subtype, distinct gene expression patterns were correlated with response to appendectomy. Interestingly, although in both subtypes activity was associated with immune activation, in the stromal group, this was a predominantly innate response, whereas in the epithelial group, the response was more adaptive in nature. Conclusions: In patients with UC two distinct phenotypic subtypes of appendix were observed. Although both groups had the potential to respond to appendectomy, response was associated with different immune activity patterns in each group. These data strongly suggest that there may be two individual mechanism of action for appendectomy in UC, which will be important to account for in future studies.
Open AccessResponse to Appendectomy in Active Ulcerative Colitis Depends on Appendiceal Phenotypic Subtype Combined With Distinct Immunological Activity
Background: Recent clinical trials have shown a promising role for appendectomy in the treatment of ulcerative colitis (UC). However, as with medical treatment, only a subset of patients responds to the intervention. A lack of predictive markers and knowledge on the mechanism of action of appendectomy in UC currently precludes affective patient selection. Methods: We performed transcriptional profiling and cellular deconvolution on the appendices obtained in the course of the recent clinical studies. Data were verified by immunohistochemistry. Results: When comparing responders to nonresponders, initially very few differentially expressed genes were observed (7 up and 6 down). However, unsupervised clustering revealed a dichotomy in the samples which was the results of underlying phenotypic differences. One group mainly displayed stromal characteristic, whereas the other expressed intestinal epithelial genes. These data were verified by deconvolution and immunohistochemistry. Importantly, within each subtype, distinct gene expression patterns were correlated with response to appendectomy. Interestingly, although in both subtypes activity was associated with immune activation, in the stromal group, this was a predominantly innate response, whereas in the epithelial group, the response was more adaptive in nature. Conclusions: In patients with UC two distinct phenotypic subtypes of appendix were observed. Although both groups had the potential to respond to appendectomy, response was associated with different immune activity patterns in each group. These data strongly suggest that there may be two individual mechanism of action for appendectomy in UC, which will be important to account for in future studies.
- Open Access
- 7 February 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (1) , e70177
Histopathological Findings of Appendix Specimens in Quiescent Ulcerative Colitis: Correlations With Clinical Outcomes in the ACCURE Trial
Background: The ACCURE trial demonstrated that appendicectomy reduces relapse rates within 1 year in patients with ulcerative colitis (UC) in remission. We aimed to explore appendiceal histopathology in quiescent UC and assess its association with postoperative relapse. Methods: Appendix specimens from Dutch participants in the ACCURE trial were reassessed by a blinded gastrointestinal pathologist using the Robarts Histopathology Index (RHI; range 0–33). Active appendiceal inflammation was defined as RHI > 3. Clinical data, preoperative endoscopic findings including peri‐appendiceal red patch (PARP), and outcomes were correlated with histopathological findings. Inter‐observer agreement between local and central scoring was assessed, along with relapse‐free survival in relation to RHI severity. Results: Of 65 patients, 49 (75.4%) maintained remission and 16 (24.6%) relapsed within one year. Active inflammation was present in 55.4% (36/65). Inter‐observer agreement was moderate ( κ = 0.47, 95% CI 0.29–0.64, p < 0.001). Inflammation was more frequent in patients diagnosed at a younger age (median 28 vs. 34 years, p = 0.09), and greater in those with PARP (RHI 15.5 vs. 5.0, p = 0.005). Extensive epithelial neutrophil involvement (> 5% of crypts) was associated with higher relapse rates (44.4% vs. 18.0%, p = 0.05). Relapsing patients also had larger appendiceal diameters (median 9 vs. 7 mm, p = 0.03). Conclusion: Active appendiceal inflammation is prevalent in quiescent UC and showed a trend toward association with relapse risk. Although the benefit of appendicectomy in this group cannot be confirmed on these data alone, the finding might be clinically relevant as relapse rates are significantly reduced in the appendicectomy group.
- 7 February 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (1) , e70177
Open AccessHistopathological Findings of Appendix Specimens in Quiescent Ulcerative Colitis: Correlations With Clinical Outcomes in the ACCURE Trial
Background: The ACCURE trial demonstrated that appendicectomy reduces relapse rates within 1 year in patients with ulcerative colitis (UC) in remission. We aimed to explore appendiceal histopathology in quiescent UC and assess its association with postoperative relapse. Methods: Appendix specimens from Dutch participants in the ACCURE trial were reassessed by a blinded gastrointestinal pathologist using the Robarts Histopathology Index (RHI; range 0–33). Active appendiceal inflammation was defined as RHI > 3. Clinical data, preoperative endoscopic findings including peri‐appendiceal red patch (PARP), and outcomes were correlated with histopathological findings. Inter‐observer agreement between local and central scoring was assessed, along with relapse‐free survival in relation to RHI severity. Results: Of 65 patients, 49 (75.4%) maintained remission and 16 (24.6%) relapsed within one year. Active inflammation was present in 55.4% (36/65). Inter‐observer agreement was moderate ( κ = 0.47, 95% CI 0.29–0.64, p < 0.001). Inflammation was more frequent in patients diagnosed at a younger age (median 28 vs. 34 years, p = 0.09), and greater in those with PARP (RHI 15.5 vs. 5.0, p = 0.005). Extensive epithelial neutrophil involvement (> 5% of crypts) was associated with higher relapse rates (44.4% vs. 18.0%, p = 0.05). Relapsing patients also had larger appendiceal diameters (median 9 vs. 7 mm, p = 0.03). Conclusion: Active appendiceal inflammation is prevalent in quiescent UC and showed a trend toward association with relapse risk. Although the benefit of appendicectomy in this group cannot be confirmed on these data alone, the finding might be clinically relevant as relapse rates are significantly reduced in the appendicectomy group.
- 15 December 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (1)
Modified-two-stage versus three-stage approach in ileoanal pouch surgery for ulcerative colitis
Background and Aims: The necessity of diverting loop-ileostomy after a staged ileoanal pouch for ulcerative colitis (UC) remains unclear. This study aimed to compare postoperative outcomes between modified-two-stage and three-stage ileoanal pouch procedures for UC. Methods: This retrospective cohort study included patients ≥18 years with UC or unclassified inflammatory bowel disease who underwent modified-two-stage or three-stage ileoanal pouch surgery from 2016 to 2021 in six European centers, with a follow-up of more than 12 months. The primary outcome was stoma-free rate at the end of follow-up. Secondary outcomes included perioperative practise, length of hospital stay, anastomotic leakage rate, and timing of diagnosis and treatment. Results: Overall, 370 patients were included, of whom 228 (61.6%) underwent a modified-two-stage approach and 142 (38.4%) a three-stage approach. The median length of follow-up was 3.6 years (range: 1.0-7.7). Stoma-free rate was 93.8% (213/227) in modified-two-stage patients and 91.5% (130/142) in three-stage patients (P = .404). Notably, 78.4% of modified-two-stage patients never required an ileostomy, while the remaining 21.6% did receive a secondary ileostomy. While the median length of hospital stay for pouch surgery was longer in the modified-two-stage group, total median length of hospital stay after 1 year was shorter (median 7.0 days [IQR 6.0-11.0] vs 9.0 days [IQR 7.0-12.5], P = .015). The Clavien–Dindo score was higher than II in 22.6% of modified-two-stage patients and in 8.7% of three-stage patients (P < .001). Anastomotic leakage rate was higher after the modified-two-stage procedure (18% vs 5%, P < .001), but diagnosis and treatment occurred earlier (86% within 21 days vs 43%, P = .009). Conclusions: Both approaches have comparable high stoma-free rates at the end of follow-up. Modified-two-stage avoids a temporary stoma in more than 75% of patients, but has a significantly higher rate of anastomotic leakages. Active and early surveillance of the anastomosis after three-stage procedures could improve postoperative outcomes in this group.
- 15 December 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (1)
Modified-two-stage versus three-stage approach in ileoanal pouch surgery for ulcerative colitis
Background and Aims: The necessity of diverting loop-ileostomy after a staged ileoanal pouch for ulcerative colitis (UC) remains unclear. This study aimed to compare postoperative outcomes between modified-two-stage and three-stage ileoanal pouch procedures for UC. Methods: This retrospective cohort study included patients ≥18 years with UC or unclassified inflammatory bowel disease who underwent modified-two-stage or three-stage ileoanal pouch surgery from 2016 to 2021 in six European centers, with a follow-up of more than 12 months. The primary outcome was stoma-free rate at the end of follow-up. Secondary outcomes included perioperative practise, length of hospital stay, anastomotic leakage rate, and timing of diagnosis and treatment. Results: Overall, 370 patients were included, of whom 228 (61.6%) underwent a modified-two-stage approach and 142 (38.4%) a three-stage approach. The median length of follow-up was 3.6 years (range: 1.0-7.7). Stoma-free rate was 93.8% (213/227) in modified-two-stage patients and 91.5% (130/142) in three-stage patients (P = .404). Notably, 78.4% of modified-two-stage patients never required an ileostomy, while the remaining 21.6% did receive a secondary ileostomy. While the median length of hospital stay for pouch surgery was longer in the modified-two-stage group, total median length of hospital stay after 1 year was shorter (median 7.0 days [IQR 6.0-11.0] vs 9.0 days [IQR 7.0-12.5], P = .015). The Clavien–Dindo score was higher than II in 22.6% of modified-two-stage patients and in 8.7% of three-stage patients (P < .001). Anastomotic leakage rate was higher after the modified-two-stage procedure (18% vs 5%, P < .001), but diagnosis and treatment occurred earlier (86% within 21 days vs 43%, P = .009). Conclusions: Both approaches have comparable high stoma-free rates at the end of follow-up. Modified-two-stage avoids a temporary stoma in more than 75% of patients, but has a significantly higher rate of anastomotic leakages. Active and early surveillance of the anastomosis after three-stage procedures could improve postoperative outcomes in this group.
- Open Access
- 8 September 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (5)
Anastomotic leakage after ileoanal pouch surgery: risk factors and salvage rate
Background: Chronic anastomotic leakage (AL) is the most common cause of pouch failure after restorative proctocolectomy with ileal pouch–anal anastomosis for ulcerative colitis. This study investigated factors associated with AL and successful salvage of leaking anastomoses after ileoanal pouch surgery. Method: This multicentre retrospective cohort study included patients aged ≥ 18 years with ulcerative colitis or unclassified inflammatory bowel disease who underwent ileoanal pouch surgery between 2016 and 2021 in six European centres, with a > 12-month follow-up. The primary outcome was AL rate. Secondary outcomes included factors associated with AL occurrence, timing of AL diagnosis (early (< 21 days) versus late), AL management, AL salvage rate, and stoma-free survival. Results: Overall, 411 patients were included, of whom 13.6% (56) had a diagnosed AL. The rate of AL was significantly higher in low-volume (less than ten procedures annually) centres (28.0% versus 12.7%; P = 0.031). Of the 56 ALs, 44 were diagnosed as early leaks and 12 were diagnosed as late leaks. A three-stage approach was associated with late diagnosis and treatment. AL was managed using various techniques, including diverting ileostomy, antibiotics, and drainage. The overall AL salvage rate was 85.4%, but increased to 92% when diagnosed and treated early (compared with 60% when diagnosed and treated late; P = 0.010). Successful AL salvage was associated with long-term stoma-free status (P = 0.002). The median follow-up was 3.8 years (range 1.0–8.1 years). The long-term stoma-free rate was 95.5% in patients with AL diagnosed and treated early, but only 41.7% when diagnosed and treated late (P < 0.001). Conclusion: Early diagnosis and treatment of AL diminishes the negative effect of AL after ileoanal pouch surgery. Proactive anastomotic assessment enable early diagnosis and management, especially in patients undergoing a three-stage approach.
- 8 September 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (5)
Open AccessAnastomotic leakage after ileoanal pouch surgery: risk factors and salvage rate
Background: Chronic anastomotic leakage (AL) is the most common cause of pouch failure after restorative proctocolectomy with ileal pouch–anal anastomosis for ulcerative colitis. This study investigated factors associated with AL and successful salvage of leaking anastomoses after ileoanal pouch surgery. Method: This multicentre retrospective cohort study included patients aged ≥ 18 years with ulcerative colitis or unclassified inflammatory bowel disease who underwent ileoanal pouch surgery between 2016 and 2021 in six European centres, with a > 12-month follow-up. The primary outcome was AL rate. Secondary outcomes included factors associated with AL occurrence, timing of AL diagnosis (early (< 21 days) versus late), AL management, AL salvage rate, and stoma-free survival. Results: Overall, 411 patients were included, of whom 13.6% (56) had a diagnosed AL. The rate of AL was significantly higher in low-volume (less than ten procedures annually) centres (28.0% versus 12.7%; P = 0.031). Of the 56 ALs, 44 were diagnosed as early leaks and 12 were diagnosed as late leaks. A three-stage approach was associated with late diagnosis and treatment. AL was managed using various techniques, including diverting ileostomy, antibiotics, and drainage. The overall AL salvage rate was 85.4%, but increased to 92% when diagnosed and treated early (compared with 60% when diagnosed and treated late; P = 0.010). Successful AL salvage was associated with long-term stoma-free status (P = 0.002). The median follow-up was 3.8 years (range 1.0–8.1 years). The long-term stoma-free rate was 95.5% in patients with AL diagnosed and treated early, but only 41.7% when diagnosed and treated late (P < 0.001). Conclusion: Early diagnosis and treatment of AL diminishes the negative effect of AL after ileoanal pouch surgery. Proactive anastomotic assessment enable early diagnosis and management, especially in patients undergoing a three-stage approach.
- Open Access
- 23 January 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (2)
The impact of advanced medical therapies on time to resection and colorectal cancer outcomes in ulcerative colitis patients undergoing colectomy
Background: We aimed to evaluate the impact of advanced medical therapies (biologicals and small molecules) on time to colectomy and oncological outcomes in ulcerative colitis (UC). Methods: This cohort study included UC patients who underwent colectomy between 2003 and 2022 at 2 referral centers in Belgium and the Netherlands. Exposure was the use of advanced medical therapies. Primary outcomes were time to colectomy and colorectal cancer (CRC) rate, compared between 4 periods: P1 (2003-2007), P2 (2008-2012), P3 (2013-2017), and P4 (2018-2022). Secondary outcomes were oncological outcomes, including incidental cancers found unexpectedly in resection specimens or during endoscopic follow-up for medication switch. Results: Among 716 patients, the usage of advanced therapies increased from 36.8% in P1 to 89.7% in P4 (P < .0001). Median time to colectomy remained comparable (P1: 7.1 years [interquartile ranges (IQR), 2.8-12.9] vs P4: 7.2 years [IQR, 2.7-14.6]; P = not significant). Colectomy and colorectal cancer was diagnosed in 72 (10.1%) patients, with no significant change over time (P = .44). Proportion of CRC was lower in patients treated with advanced therapies (4.7% vs 23.6%, P < .0001) and related to a shorter follow-up (median 6.1 vs 10.3 years, P < .0001). Advanced therapy patients had higher incidental cancer rates (37.5% vs 8.3%, P = .002), which was associated with reduced CRC-related survival (HR for CRC-related death: 3.3, 95% CI 1.17-9.4; P = .02). Conclusion: Despite increased usage of advanced medical therapies, time to resection and CRC rates have remained unchanged in UC patients undergoing colectomy over the past 2 decades. Advanced therapy patients had higher incidental cancers rates, associated with decreased CRC survival. Awareness of timely colectomy is crucial for this group.
- 23 January 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (2)
Open AccessThe impact of advanced medical therapies on time to resection and colorectal cancer outcomes in ulcerative colitis patients undergoing colectomy
Background: We aimed to evaluate the impact of advanced medical therapies (biologicals and small molecules) on time to colectomy and oncological outcomes in ulcerative colitis (UC). Methods: This cohort study included UC patients who underwent colectomy between 2003 and 2022 at 2 referral centers in Belgium and the Netherlands. Exposure was the use of advanced medical therapies. Primary outcomes were time to colectomy and colorectal cancer (CRC) rate, compared between 4 periods: P1 (2003-2007), P2 (2008-2012), P3 (2013-2017), and P4 (2018-2022). Secondary outcomes were oncological outcomes, including incidental cancers found unexpectedly in resection specimens or during endoscopic follow-up for medication switch. Results: Among 716 patients, the usage of advanced therapies increased from 36.8% in P1 to 89.7% in P4 (P < .0001). Median time to colectomy remained comparable (P1: 7.1 years [interquartile ranges (IQR), 2.8-12.9] vs P4: 7.2 years [IQR, 2.7-14.6]; P = not significant). Colectomy and colorectal cancer was diagnosed in 72 (10.1%) patients, with no significant change over time (P = .44). Proportion of CRC was lower in patients treated with advanced therapies (4.7% vs 23.6%, P < .0001) and related to a shorter follow-up (median 6.1 vs 10.3 years, P < .0001). Advanced therapy patients had higher incidental cancer rates (37.5% vs 8.3%, P = .002), which was associated with reduced CRC-related survival (HR for CRC-related death: 3.3, 95% CI 1.17-9.4; P = .02). Conclusion: Despite increased usage of advanced medical therapies, time to resection and CRC rates have remained unchanged in UC patients undergoing colectomy over the past 2 decades. Advanced therapy patients had higher incidental cancers rates, associated with decreased CRC survival. Awareness of timely colectomy is crucial for this group.
- Open Access
- 26 March 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-11
Clinical statistical analysis plan for the ACCURE trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicentre trial
Background: The primary treatment of ulcerative colitis (UC) is medical therapy using a standard step-up approach. An appendectomy might modulate the clinical course of UC, decreasing the incidence of relapses and reducing need for medication. The objective of the ACCURE trial is to assess the efficacy of laparoscopic appendectomy in addition to standard medical treatment in maintaining remission in UC patients. This article presents the statistical analysis plan to evaluate the outcomes of the ACCURE trial. Design and methods: The ACCURE trial was designed as a multicentre, randomised controlled trial. UC patients with a new diagnosis or a disease relapse within the past 12 months, treated with 5-ASA, corticosteroids, or immunomodulators until complete clinical and endoscopic remission (defined as total Mayo score < 3 with endoscopic subscore of 0 or 1), were counselled for inclusion. Also, patients previously treated with biologicals who had a washout period of at least 3 months were considered for inclusion. Patients were randomised (1:1) to laparoscopic appendectomy plus maintenance treatment or a control group (maintenance therapy only). The primary outcome is the 1-year UC relapse rate (defined as a total Mayo-score ≥ 5 with endoscopic subscore of 2 or 3, or clinically as an exacerbation of symptoms and rectal bleeding or FCP > 150 or intensified medical therapy other than 5-ASA therapy). Secondary outcomes include number of relapses per patient, time to first relapse, disease activity, number of colectomies, medication usage, and health-related quality of life. Discussion: The ACCURE trial will provide comprehensive evidence whether adding an appendectomy to maintenance treatment is superior to maintenance treatment only in maintaining remission in UC patients. Trial registration: Dutch Trial Register (NTR) NTR2883. Registered May 3, 2011. ISRCTN, ISRCTN60945764. Registered August 12, 2019.
- 26 March 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-11
Open AccessClinical statistical analysis plan for the ACCURE trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicentre trial
Background: The primary treatment of ulcerative colitis (UC) is medical therapy using a standard step-up approach. An appendectomy might modulate the clinical course of UC, decreasing the incidence of relapses and reducing need for medication. The objective of the ACCURE trial is to assess the efficacy of laparoscopic appendectomy in addition to standard medical treatment in maintaining remission in UC patients. This article presents the statistical analysis plan to evaluate the outcomes of the ACCURE trial. Design and methods: The ACCURE trial was designed as a multicentre, randomised controlled trial. UC patients with a new diagnosis or a disease relapse within the past 12 months, treated with 5-ASA, corticosteroids, or immunomodulators until complete clinical and endoscopic remission (defined as total Mayo score < 3 with endoscopic subscore of 0 or 1), were counselled for inclusion. Also, patients previously treated with biologicals who had a washout period of at least 3 months were considered for inclusion. Patients were randomised (1:1) to laparoscopic appendectomy plus maintenance treatment or a control group (maintenance therapy only). The primary outcome is the 1-year UC relapse rate (defined as a total Mayo-score ≥ 5 with endoscopic subscore of 2 or 3, or clinically as an exacerbation of symptoms and rectal bleeding or FCP > 150 or intensified medical therapy other than 5-ASA therapy). Secondary outcomes include number of relapses per patient, time to first relapse, disease activity, number of colectomies, medication usage, and health-related quality of life. Discussion: The ACCURE trial will provide comprehensive evidence whether adding an appendectomy to maintenance treatment is superior to maintenance treatment only in maintaining remission in UC patients. Trial registration: Dutch Trial Register (NTR) NTR2883. Registered May 3, 2011. ISRCTN, ISRCTN60945764. Registered August 12, 2019.